Please login to the form below
antibiotic development
This page shows the latest antibiotic development news and features for those working in and with pharma, biotech and healthcare.
Sandoz to invest €50m in Austrian manufacturing facility to meet global antibiotic demand
Amoxicillin and other vital penicillin products will benefit from the investment
Latest news
-
Shionogi, GARDP and CHAI team up to increase antibiotic access worldwide
Shionogi has teamed up with the Global Antibiotic Research and Development Partnership (GARDP) and the Clinton Health Access Initiative (CHAI) improve global access to antibiotics. ... Shionogi is proud to work on such an innovative licence agreement
-
UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme
This pilot is intended to encourage drug developers to resume and increase research and development into new antibiotic medications, given that this area is lacking in innovation due to the economic ... Shionogi’s novel antibiotic is designed to use
-
Novartis’ Sandoz division announces antibiotic manufacturing plan
Antibiotic research and development has seen a renewed focus over the last few years, as antibiotic resistance rapidly becomes a significant threat to global health. ... Although the Sandoz agreement does not include the development of next-generation
-
Researchers discover new antibiotic using AI
instance where novel types of antibiotic have been discovered using the AI method. ... GlaxoSmithKline is one of the sole big pharma players still developing new antibiotics, with a new-class antibiotic currently in phase 3 development for use in
-
Shionogi scores FDA approval for new cUTI antibiotic
The approval comes at a time of increasing antibiotic resistance around the world. ... The development of new drugs to treat antibiotic resistant germs is well overdue, as pharma companies have halted research in this area as there is no significant
More from news
Approximately 1 fully matching, plus 29 partially matching documents found.
Latest Intelligence
-
The fight against antimicrobial resistance
As there is a direct relationship between antibiotic use and the development of resistance, over-use of antibiotics, which is the leading cause of antimicrobial resistance, must be dramatically reduced if ... Clinicians involved in the recent Primary
-
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
This combination will be critical to strengthening and accelerating antibiotic development. ... The AMR Action Fund will provide a bridge for innovative antibiotic candidates in the pipeline through the most challenging later stages of drug development,
-
How COVID-19 is accelerating the threat of antimicrobial resistance
This included the Global Antibiotic Research and Development Partnership (GARDP) and the British Society for Antimicrobial Chemotherapy (BSAC). ... Other organisations across Europe also called on HCPs not to neglect antibiotic stewardship.
-
Combining therapies and combining research
This leaves the fight for antibiotic survival, arguably one of the most urgent fields of drug development, to smaller, more nimble biopharmaceutical companies. ... Wholly focused on the discovery and development of new antibiotic combinations, it has
-
Curbing the rise of drug resistance
The KPMG report urges governments and global life sciences businesses to invest more in antibiotic research and development, yet, the recent acquisition of Cubist Pharmaceuticals by Merck &Co. ... distribution. This improves incentives for development
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest appointments
-
Henry Skinner has been appointed as the first CEO of the AMR Action Fund
The AMR Action Fund is aiming to strengthen and accelerate antibiotic development. ... Henry Skinner (pictured above) has been appointed the first chief executive officer of the AMR Action Fund, an initiative aiming to strengthen and accelerate
-
Ex-Pfizer executive Ed Mascioli joins Affinium as CEO
The appointments come as Affinium prepares to progress the development of its antibiotic AFN-1252 for staphylococcal infections.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Antibiotic Resistance: Alarm bells ring louder than ever
treatments. Challenges of antibiotic development There have been few new classes of antibacterial discovered in the last 30 years, although the recent publication in Nature on the discovery of teixobactin may ... Another angle is the development of small
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Ketchum appoints Conor Nash as global chief financial officer and chief operating officer
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
